Subject Area and Research Team: X. Clinical trials and innovation

Area and Research Team: X. Clinical trials and innovation

Research topics

1. Antithrombotic treatment in patients with acute coronary syndrome (ACS) and atrial fibrillation (AF) – we hypothesize that the off-label regimen of dual antithrombotic therapy including dabigatran and reduced dose ticagrelor is superior regarding bleeding risk and non-inferior in terms of ischaemic protection, compared to the standard triple therapy in patients with AF and after ACS, treated with PCI and stenting

2. Multivessel versus staged revascularization in acute myocardial infarction (AMI) – to investigate whether in patients with AMI, PCI of non-culprit lesions reduces the risk of cardiovascular death or AMI

3. The International Takotsubo Registry – a consortium of European/US centres to investigate clinical features, prognostic predictors, and outcome of takotsubo cardiomyopathy

4. Implantation of REDUCER device in ANOCA patients – we hypothesize that the implantation of the Reducer device may essentially improve ischemia, symptom status and quality of life of ANOCA patients

5. Fractional flow reserve (FFR) in AMI patients – to investigate the feasibility of FFR in acute course of AMI (FFR-AMI study)

6. The heart valve for life: polymeric off-the–shelve materials that aim to replace the biovalve and mimize the use of anti-coagulation


Coordinator #1 Coordinator #2
Name and surname
Miłosz J. Jaguszewski
Paul Grundeman
Academic degree Prof. Dr. Habil. Prof.
Employment unit I Department of Cardiology Translational Medicine Centre
Polish Platform of Medical Research Prof. Dr. Habil. Miłosz J. Jaguszewski
Phone number +48 58 34 925 00 +48 58 34 925 27

photos Paweł Sudara/MUG

Research Team: X. Clinical trials and innovation

Team Members: X. Clinical trials and innovation (182 KB)

Feel free to contact one of our coordinators to join our Research Team.

Key current projects

1. New Strategy of Dual Antithrombotic Therapy with Dabigatran and Ticagrelor in Patients with Acute Coronary Syndrome and non-valvular Atrial Fibrillation undergoing Percutaneous Coronary Intervention (ADONIS – PCI Study)

2. MULTivessel Immediate versus STAged RevaScularization in Acute Myocardial Infarction – The MULTISTARS AMI Trial

3. International Takotsubo Registry – clinical features and outcomes of takotsubo (stress) cardiomyopathy

4. A sham-controlled, double-blinded study to assess the safety and efficacy of the coronary sinus REDUCEr in patients with refractory Angina and No Obstructive Coronary Artery disease: a randomized trial (REDUCE-ANOCA trial)

5. Evaluation of safety and efficacy of two ticagrelor-based de-escalation antiplatelet strategies in acute coronary syndrome: the randomized, multicenter, double-blind ELECTRA-SIRIO 2 study

6. Injury to the hand and feet microcirculation during chemotherapy-mitigation/prevention of (chronic) symptoms by smart novel devices

7. The spacemaker: least invasive subxipoid access to the pericardial space for cardiac tissue ablation/epicardial pacing and cardiac regenerative therapies

Key grants

Funding agency/grant numer Title of the project Years
1. Agencja Badań Medycznych: 2019.ABM.01.00027 New Strategy of Dual Antithrombotic Therapy with Dabigatran and Ticagrelor in Patients with Acute Coronary Syndrome and non-valvular Atrial Fibrillation (ADONIS-PCI Study) 2020-2025
2. Agencja Badań Medycznych: 2019.ABM.01.00026 A Randomized, Single center, Double-Blind, Placebo Controlled, Parallel-Group, Event-Driven, Group-Sequential Study With Open-Label Extension Period to Assess the Efficacy and Safety of Metoprolol as Add-On Treatment to Standard of Care in Children Aged ≥ 8 to < 17 years with Duchenne Muscular Distrophy 2020-2023

International cooperation

Foreign partner (unit name) Principal investigator(s) Area of cooperation
1. Vascular, Heart and Lung Associates, College of Medicine, Phoenix, The University of Arizona, USA Prof dr hab n med. Richard Hauser REDUCER implantation
2. Chest Pain and Coronary Physiology Clinic, Division of Ischemic Heart Disease and Critical Care, Department of Cardiovascular Medicine Prof. dr hab. n med. Amir Lerman REDUCER implantation
3. Imperial College National Heart and Lung Institute Guy Scadding Building Dovehouse Street, London Prof. dr hab. n med. Thomas Luscher Takotsubo registry, ADONIS-PCI study
4. Department of Cardiology, University Hospital Zurich, Switzerland Prof. dr hab. n. med. Christian Templin Takotsubo Registry
5. Division of Cardiology, Interventional Cardiology, Tel Aviv Medical Center, Israel Prof. dr hab. n med. Shmuel Banai REDUCER implantation

Key publications

1. Templin et al, Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy, N Engl J Med. 2015 Sep 3;373(10):929-38. doi: 10.1056/NEJMoa1406761.

2. Napp LC, Cammann VL, Jaguszewski M, Coexistence and outcome of coronary artery disease in Takotsubo syndrome. Eur Heart J 2020 Jun 2;ehaa210. doi: 10.1093/eurheartj/ehaa210

3. Mickiewicz A, Futema M, Higher Responsiveness to Rosuvastatin in Polygenic versus Monogenic Hypercholesterolaemia: A Propensity Score Analysis. Life (Basel). 2020 May 20;10(5):73. doi: 10.3390/life10050073.

4. Wańha W, Mielczarek M, Gilis-Malinowska N, Safety and Efficacy of Embolic Protection Devices in Saphenous Vein Graft Interventions: A Propensity Score Analysis-Multicenter SVG PCI PROTECTA Study. J Clin Med. 2020 Apr 22;9(4):1198. doi: 10.3390/jcm9041198.

5. Wdowczyk J, Mielczarek M, Ciecwierz D, Jaguszewski M, Bioresorbable vascular scaffolds to treat coronary allograft vasculopathy: Insights from optical coherence tomography imaging. J Heart Lung Transplant. 2018 Mar;37(3):418-420. doi: 10.1016/j.healun.2017.10.015. Epub 2017 Oct 26.